According to the Zhitong Finance App, Hanson Pharmaceuticals (03692.HK) announced that GSK has been granted breakthrough therapy certification (BTD) by the US Food and Drug Administration (FDA) for GSK5764227 (GSK'227, also known as HS-20093). This B7-H3 targeting antibody drug conjugate (ADC) is being evaluated for treatment of adult patients with recurrent or refractory osteosarcoma (bone cancer) with previous second-line treatment progression.

Zhitongcaijing · 01/07 11:25
According to the Zhitong Finance App, Hanson Pharmaceuticals (03692.HK) announced that GSK has been granted breakthrough therapy certification (BTD) by the US Food and Drug Administration (FDA) for GSK5764227 (GSK'227, also known as HS-20093). This B7-H3 targeting antibody drug conjugate (ADC) is being evaluated for treatment of adult patients with recurrent or refractory osteosarcoma (bone cancer) with previous second-line treatment progression.